Sandoz Group

Historical price data

Sandoz is a mission-driven global leader in generics and biosimilars, focused on expanding sustainable access to medicines. Its strategic independence, following the 2023 spin-off, allows for dedicated capital allocation and agile execution in a market driven by patent expiries and cost containment. The company's dual-pillar strategy encompasses a deep pipeline of complex generics and a leading portfolio of biosimilars, supported by world-class development and manufacturing capabilities. With a commercial reach serving approximately 500 million patients annually, Sandoz is positioned to capitalize on significant market opportunities while delivering on its purpose.

Integrated platform for complex generic formulation and comprehensive biosimilar development, centered on advanced analytical characterization to demonstrate similarity to reference products.

Sandoz competes with large global generics firms (e.g., Teva, Viatris) on scale and cost, and with focused biosimilar players (e.g., Amgen, Celltrion) on development speed and commercialization. Its integrated global capabilities and strong brand provide key differentiators.